Drug intelligence / Profile preview

DUP9 ADC

Development stage: Unknown
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**DUP9 ADC** is an investigational antibody-drug conjugate (ADC) featuring DUP9, a novel derivative of ecteinascidin (also known as trabectedin or ET-743), as the cytotoxic payload. Ecteinascidins are marine-derived alkaloids that bind to the minor groove of DNA, inducing DNA damage through alkylation and bend formation, leading to cell cycle arrest and apoptosis, particularly in tumor cells. This ADC demonstrates promising therapeutic efficacy in preclinical models of cancer, with a novel mechanism distinct from conventional ADC payloads targeting tubulin or topoisomerase.

Targets

DNA

Beyond the preview

Go deeper on DUP9 ADC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DUP9 ADC.

Explore the full profile